Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FAP-exatecan
- Development stage
- Unknown
- Lead developer
- Avacta
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
FAP-exatecan (AVA6103) is an investigational peptide drug conjugate (PDC) developed by Avacta Therapeutics using its proprietary pre|CISION® tumor-activated oncology delivery platform. The drug consists of the potent topoisomerase I inhibitor exatecan linked to a peptide that is specifically cleaved by Fibroblast Activation Protein (FAP), a protease highly expressed in the tumor microenvironment of many solid tumors. This design enables the selective release of the cytotoxic payload within the tumor while sparing normal tissues, potentially improving the therapeutic index compared to conventional exatecan. FAP-exatecan is designed for sustained tumor drug exposure and has demonstrated a bystander effect on FAP-negative cancer cells in preclinical models. It is currently being evaluated in Phase 1 clinical trials for the treatment of various solid tumors, including pancreatic, cervical, gastric, and small cell lung cancers.
- Other names
- FAP-exatecanFAP-Exd
02
Targets
FAP (Fibroblast activation protein alpha)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on FAP-exatecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FAP-exatecan.